SK280130B6 - Komplex zrážacieho faktora ix, spôsob jeho výroby, - Google Patents
Komplex zrážacieho faktora ix, spôsob jeho výroby, Download PDFInfo
- Publication number
- SK280130B6 SK280130B6 SK211-92A SK21192A SK280130B6 SK 280130 B6 SK280130 B6 SK 280130B6 SK 21192 A SK21192 A SK 21192A SK 280130 B6 SK280130 B6 SK 280130B6
- Authority
- SK
- Slovakia
- Prior art keywords
- factor
- complex
- protein
- vitamin
- aqueous mixture
- Prior art date
Links
- 108010076282 Factor IX Proteins 0.000 title claims abstract description 68
- 238000000034 method Methods 0.000 title claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 4
- 102000013831 Coagulation factor IX Human genes 0.000 title abstract 2
- 229940105774 coagulation factor ix Drugs 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title description 4
- 229960004222 factor ix Drugs 0.000 claims abstract description 75
- 102100022641 Coagulation factor IX Human genes 0.000 claims abstract description 66
- 239000000203 mixture Substances 0.000 claims abstract description 12
- 229920000642 polymer Polymers 0.000 claims abstract description 10
- 238000004519 manufacturing process Methods 0.000 claims abstract description 8
- 108091005605 Vitamin K-dependent proteins Proteins 0.000 claims abstract description 7
- 125000001165 hydrophobic group Chemical group 0.000 claims abstract description 6
- 239000003114 blood coagulation factor Substances 0.000 claims description 15
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims description 14
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 13
- 108010094028 Prothrombin Proteins 0.000 claims description 11
- 102100027378 Prothrombin Human genes 0.000 claims description 10
- 229940039716 prothrombin Drugs 0.000 claims description 10
- 208000009429 hemophilia B Diseases 0.000 claims description 4
- 239000012678 infectious agent Substances 0.000 claims description 4
- 206010016077 Factor IX deficiency Diseases 0.000 claims description 2
- 102000029301 Protein S Human genes 0.000 claims description 2
- 108010066124 Protein S Proteins 0.000 claims description 2
- 230000009918 complex formation Effects 0.000 claims description 2
- 229940024790 prothrombin complex concentrate Drugs 0.000 claims description 2
- 208000031220 Hemophilia Diseases 0.000 claims 1
- 208000009292 Hemophilia A Diseases 0.000 claims 1
- 101800004937 Protein C Proteins 0.000 claims 1
- 102000017975 Protein C Human genes 0.000 claims 1
- 229940096437 Protein S Drugs 0.000 claims 1
- 101800001700 Saposin-D Proteins 0.000 claims 1
- 125000000129 anionic group Chemical group 0.000 claims 1
- 239000003945 anionic surfactant Substances 0.000 claims 1
- 125000002091 cationic group Chemical group 0.000 claims 1
- 239000003093 cationic surfactant Substances 0.000 claims 1
- 230000000536 complexating effect Effects 0.000 claims 1
- 239000002736 nonionic surfactant Substances 0.000 claims 1
- 229960000856 protein c Drugs 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 abstract description 9
- 230000002209 hydrophobic effect Effects 0.000 abstract description 8
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 5
- 108010062466 Enzyme Precursors Proteins 0.000 abstract 1
- 102000010911 Enzyme Precursors Human genes 0.000 abstract 1
- 229940127557 pharmaceutical product Drugs 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000010828 elution Methods 0.000 description 6
- 239000003599 detergent Substances 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- 108010014173 Factor X Proteins 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- GUPXYSSGJWIURR-UHFFFAOYSA-N 3-octoxypropane-1,2-diol Chemical compound CCCCCCCCOCC(O)CO GUPXYSSGJWIURR-UHFFFAOYSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000003463 adsorbent Substances 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 208000019838 Blood disease Diseases 0.000 description 1
- 102100037815 Fas apoptotic inhibitory molecule 3 Human genes 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101000878510 Homo sapiens Fas apoptotic inhibitory molecule 3 Proteins 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000003686 blood clotting factor concentrate Substances 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 238000001470 plasma protein fractionation Methods 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- STCOOQWBFONSKY-UHFFFAOYSA-N tributyl phosphate Chemical compound CCCCOP(=O)(OCCCC)OCCCC STCOOQWBFONSKY-UHFFFAOYSA-N 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
- Measurement Of Velocity Or Position Using Acoustic Or Ultrasonic Waves (AREA)
- Medicinal Preparation (AREA)
- Compounds Of Unknown Constitution (AREA)
- Separation Of Suspended Particles By Flocculating Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AT0016391A AT402261B (de) | 1991-01-25 | 1991-01-25 | Komplex enthaltend den gerinnungsfaktor ix |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK280130B6 true SK280130B6 (sk) | 1999-08-06 |
Family
ID=3483232
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK211-92A SK280130B6 (sk) | 1991-01-25 | 1992-01-24 | Komplex zrážacieho faktora ix, spôsob jeho výroby, |
| SK1633-98A SK280989B6 (sk) | 1991-01-25 | 1992-01-24 | Spôsob výroby farmaceutického preparátu obsahujúceho zrážací faktor ix |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1633-98A SK280989B6 (sk) | 1991-01-25 | 1992-01-24 | Spôsob výroby farmaceutického preparátu obsahujúceho zrážací faktor ix |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US5281661A (cs) |
| EP (1) | EP0496725B1 (cs) |
| JP (2) | JP2651307B2 (cs) |
| AT (2) | AT402261B (cs) |
| CA (1) | CA2059979C (cs) |
| CZ (2) | CZ154794A3 (cs) |
| DE (1) | DE59207638D1 (cs) |
| DK (1) | DK0496725T3 (cs) |
| ES (1) | ES2098485T3 (cs) |
| FI (1) | FI100111B (cs) |
| HU (1) | HU212362B (cs) |
| SK (2) | SK280130B6 (cs) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0573605B1 (en) * | 1991-03-01 | 2000-08-30 | Rhone-Poulenc Rorer International (Holdings) Inc. | Preparation of factor ix |
| DE4342132C1 (de) * | 1993-12-10 | 1994-11-03 | Octapharma Ag | Verfahren zur Herstellung virusinaktivierte Vitamin K abhängige Plasmakomponenten sowie Protein C und Protein S enthaltender Mittel durch Membran-Chromatographie |
| US5888826A (en) * | 1994-06-30 | 1999-03-30 | Dade Behring Inc. | Combination reagent holding and test device |
| WO1996000899A1 (en) | 1994-06-30 | 1996-01-11 | Dade International Inc. | Bioactive porous partition members |
| US5602037A (en) * | 1994-06-30 | 1997-02-11 | Dade International, Inc. | Combination reagent holding and test device |
| DE19506633A1 (de) * | 1995-02-25 | 1996-08-29 | Octapharma Ag | Verfahren zur Herstellung von Faktor IX aus biologischen Quellen |
| US5714583A (en) * | 1995-06-07 | 1998-02-03 | Genetics Institute, Inc. | Factor IX purification methods |
| US5958716A (en) * | 1996-06-06 | 1999-09-28 | Dade Behring Inc. | Blood factor assay |
| WO1999022753A1 (fr) * | 1997-11-05 | 1999-05-14 | Yoshitomi Pharmaceutical Industries, Ltd. | Preparations a base du cofacteur ii de l'heparine et procede de preparation |
| WO2005033140A1 (ja) * | 2003-09-30 | 2005-04-14 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | 高純度血液凝固ｉｘ因子調製物およびその精製方法 |
| KR101146160B1 (ko) * | 2004-06-30 | 2012-07-16 | 넥타르 테라퓨틱스 | 중합체인자 ｉｘ 부분의 접합체 |
| MX2007007356A (es) * | 2004-12-23 | 2007-08-14 | Novo Nordisk Healthcare Ag | Reduccion del contenido de contaminantes proteinicos en composiciones que comprenden una proteina dependiente de la vitamina k de interes. |
| AU2010253830B2 (en) | 2009-05-27 | 2016-03-03 | Takeda Pharmaceutical Company Limited | A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use |
| CN102655853B (zh) | 2009-09-17 | 2015-07-29 | 巴克斯特卫生保健有限公司 | 透明质酸酶和免疫球蛋白的稳定的复合制剂及其使用方法 |
| JP2013544762A (ja) | 2010-09-17 | 2013-12-19 | バクスター、インターナショナル、インコーポレイテッド | 弱酸性〜中性のｐＨにおける、塩化ナトリウムを有する水性製剤を介した免疫グロブリンおよび他のタンパク質の安定化 |
| AU2011343813B2 (en) | 2010-12-15 | 2015-05-21 | Takeda Pharmaceutical Company Limited | Eluate collection using conductivity gradient |
| US9244073B2 (en) | 2011-02-25 | 2016-01-26 | Wellstat Diagnostics, Llc | Assays for detecting enzymatic activity |
| WO2025068923A2 (en) | 2023-09-26 | 2025-04-03 | Takeda Pharmaceutical Company Limited | IMMUNOGLOBULIN FORMULATIONS DEPLETED IN IgA |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2543448A1 (fr) * | 1983-04-01 | 1984-10-05 | Rhone Poulenc Spec Chim | Procede de fractionnement du plasma |
| US4820805A (en) * | 1983-07-14 | 1989-04-11 | New York Blood Center, Inc. | Undenatured virus-free trialkyl phosphate treated biologically active protein derivatives |
| AT389815B (de) * | 1984-03-09 | 1990-02-12 | Immuno Ag | Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten |
| US4721572A (en) * | 1985-07-12 | 1988-01-26 | Miles Laboratories, Inc. | Purfication of blood clotting factors and other blood proteins on non-carbohydrate sulfated matrices |
| EP0229026B1 (en) * | 1986-01-06 | 1995-11-22 | Blood Systems Inc, an Arizona not-for-profit corporation | Therapeutic blood product, means and methods of preparing same |
| JPS63108000A (ja) * | 1986-05-15 | 1988-05-12 | Green Cross Corp:The | 第８因子の精製方法 |
| US4725673A (en) * | 1986-08-29 | 1988-02-16 | Alpha Therapeutic Corporation | Plasma fraction purification using silica resin bound to a ligand |
| DE3877529T2 (de) * | 1987-10-23 | 1996-11-07 | Centre Regional De Transfusion | Herstellung von hoch-gereingtem menschlichen Faktor IX sowie anderem Plasmaproteinkonzentrat und dessen therapeutische Verwendung. |
| DE3914869C1 (cs) * | 1989-05-05 | 1990-08-09 | Biotest Pharma Gmbh, 6072 Dreieich, De |
-
1991
- 1991-01-25 AT AT0016391A patent/AT402261B/de not_active IP Right Cessation
-
1992
- 1992-01-21 US US07/822,996 patent/US5281661A/en not_active Expired - Lifetime
- 1992-01-23 ES ES92890018T patent/ES2098485T3/es not_active Expired - Lifetime
- 1992-01-23 DK DK92890018.2T patent/DK0496725T3/da not_active Application Discontinuation
- 1992-01-23 AT AT92890018T patent/ATE146220T1/de not_active IP Right Cessation
- 1992-01-23 EP EP92890018A patent/EP0496725B1/de not_active Expired - Lifetime
- 1992-01-23 DE DE59207638T patent/DE59207638D1/de not_active Expired - Lifetime
- 1992-01-24 CZ CZ941547A patent/CZ154794A3/cs not_active IP Right Cessation
- 1992-01-24 SK SK211-92A patent/SK280130B6/sk unknown
- 1992-01-24 CA CA002059979A patent/CA2059979C/en not_active Expired - Lifetime
- 1992-01-24 JP JP4010797A patent/JP2651307B2/ja not_active Expired - Fee Related
- 1992-01-24 FI FI920342A patent/FI100111B/fi active
- 1992-01-24 HU HU9200225A patent/HU212362B/hu not_active IP Right Cessation
- 1992-01-24 SK SK1633-98A patent/SK280989B6/sk unknown
- 1992-01-24 CZ CS92211A patent/CZ280297B6/cs not_active IP Right Cessation
-
1993
- 1993-11-03 US US08/146,921 patent/US5409990A/en not_active Expired - Lifetime
-
1996
- 1996-03-01 JP JP8044995A patent/JP2866047B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| ES2098485T3 (es) | 1997-05-01 |
| EP0496725A2 (de) | 1992-07-29 |
| HUT63863A (en) | 1993-10-28 |
| US5281661A (en) | 1994-01-25 |
| HU212362B (en) | 1996-06-28 |
| EP0496725A3 (en) | 1993-05-05 |
| US5409990A (en) | 1995-04-25 |
| ATA16391A (de) | 1996-08-15 |
| CA2059979C (en) | 2003-04-15 |
| FI920342L (fi) | 1992-07-26 |
| AT402261B (de) | 1997-03-25 |
| CS21192A3 (en) | 1992-08-12 |
| HU9200225D0 (en) | 1992-04-28 |
| JP2651307B2 (ja) | 1997-09-10 |
| CA2059979A1 (en) | 1992-07-26 |
| FI920342A0 (fi) | 1992-01-24 |
| CZ280297B6 (cs) | 1995-12-13 |
| JPH04295432A (ja) | 1992-10-20 |
| ATE146220T1 (de) | 1996-12-15 |
| SK280989B6 (sk) | 2000-10-09 |
| CZ280725B6 (cs) | 1996-04-17 |
| DE59207638D1 (de) | 1997-01-23 |
| CZ154794A3 (en) | 1996-04-17 |
| DK0496725T3 (da) | 1997-06-09 |
| JP2866047B2 (ja) | 1999-03-08 |
| FI100111B (fi) | 1997-09-30 |
| JPH08259449A (ja) | 1996-10-08 |
| EP0496725B1 (de) | 1996-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK280130B6 (sk) | Komplex zrážacieho faktora ix, spôsob jeho výroby, | |
| US4687664A (en) | Method of inactivating reproducible pathogens | |
| US6005082A (en) | Process for purification of factor VIII | |
| IE44507B1 (en) | Cationic material capable of reversibly fixing biological macromolecules | |
| JPH02218699A (ja) | 精製されたプロテインａ組成物及びそれらの調製方法 | |
| CA2491716A1 (en) | Processes for the preparation of fibrinogen | |
| EP0391974B1 (en) | Process for the purification of vitamin k-dependent blood clotting factors | |
| Sakamoto et al. | Studies on the interaction between heparin and mouse bone collagenase | |
| AU747274B2 (en) | Improved methods for producing factor VIII proteins | |
| JPH053480B2 (cs) | ||
| JP3043558B2 (ja) | ヒト活性化プロテインｃ調製物及びその製法 | |
| JPH02113893A (ja) | 凝固因子２、７、９およびｘの１または２以上を濃縮する方法 | |
| Josić et al. | Size-exclusion chromatography of plasma proteins with high molecular masses | |
| US5445958A (en) | Process for purifying blood clotting factors | |
| EA000222B1 (ru) | Способ получения фактора ix из биологических источников и фактор ix, полученный этим способом | |
| JPS6034916A (ja) | 第１ｘ因子および他のビタミンｋ依存性タンパク質の高純度精製 | |
| JP2926728B2 (ja) | 蛋白質含有組成物の製造方法 | |
| EP0813597B1 (en) | A process for the purification of vitamin k dependent coagulation factors by chromatography | |
| US4694074A (en) | Process for the purification of HBsAg | |
| Scherberich et al. | Bio-and immunospecific affinity chromatography of plasma membrane antigens from human kidney and renal cell carcinoma | |
| AU627446C (en) | Chemical process | |
| JPH0795894A (ja) | リポコルチンの精製方法 | |
| Kizuki et al. | Porcine pancreatic prokallikrein. II. Purification and some properties of prokallikrein A | |
| JPH01148185A (ja) | 逆相液体クロマトグラフィーによるｔ−ＰＡ精製方法 | |
| CZ2000983A3 (cs) | Způsob čištění antithrombinu III |